New Risk • Jun 05
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩153.2b (US$99.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company. Announcement • Feb 27
Daihan Pharmaceutical Co.,Ltd., Annual General Meeting, Mar 26, 2026 Daihan Pharmaceutical Co.,Ltd., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 77, sandan-ro, danwon-gu, gyeonggi-do, ansan South Korea Buy Or Sell Opportunity • Jan 20
Now 23% overvalued Over the last 90 days, the stock has fallen 6.2% to ₩27,850. The fair value is estimated to be ₩22,635, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 10.0%. Revenue is forecast to grow by 8.3% in 2 years. Earnings are forecast to grow by 2.3% in the next 2 years.